NurExone Biologic (TSXV:NRX) Total Equity : C$3.97 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Total Equity?

NurExone Biologic's total equity for the quarter that ended in Sep. 2024 was C$3.97 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

NurExone Biologic Total Equity Historical Data

The historical data trend for NurExone Biologic's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Total Equity Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Total Equity

1.51

2.85

0.25

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Equity	Get a 7-Day Free Trial									0.98	0.25	4.92	3.53	3.97

NurExone Biologic Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

NurExone Biologic's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	2.911	-	2.658
	=	0.25

NurExone Biologic's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2024 )	-	Total Liabilities(Q: Sep. 2024 )
	=	4.896	-	0.929
	=	3.97

NurExone Biologic Total Equity Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

NRXBF:USA J90:Germany

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

Executives

James Angus Wilson (bilkstys-) Richardson

10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines